Pacific Edge 2018 Annual Meeting Results

17August 2018
Company Announcement



PACIFIC EDGE ANNUAL MEETING


Summary of meeting and results of the vote

Cancer diagnostics company, Pacific Edge (NZX: PEB), held its Annual Shareholder Meeting in Dunedin today,
updating shareholders on its progress and Board and management priorities for FY19. The meeting provided strong
support for the progress the Company was making.

The Company outlined that it continues to hold firm to its purpose of establishing Cxbladder as the world’s leading
molecular diagnostic technology for the detection and management of bladder cancer. The USA healthcare market,
the world’s largest, remains the primary opportunity and investment continues to be made into realising the
significant potential.

Positive progress was made in FY18, with a number of commercial, reimbursement and coverage milestones
resulting in growing adoption and sales of Cxbladder. New Zealand’s healthcare practitioners are leading the way,
with the majority of the large public healthcare providers (DHBs) now adopting Cxbladder into use in their clinical
pathways.

The USA market remains the priority for FY19, with management focused on concluding commercial agreements
with the large institutional accounts and payers it has targeted. “There is an increased focus on bringing on board
large institutional healthcare organisations as customers and building on initial sales from the Veterans
Administration. A continuing uplift in sales is expected“ said Pacific Edge CEO David Darling.

In New Zealand the clinical validity and utility of Cxbladder is no longer questioned however additional clinical
papers are expected to be published in peer reviewed clinical journals in FY19, upholding the strong performance
of the tests providing greater evidence and reach to providers and payers globally.

The early success in Singapore is pleasing and management are working to transition healthcare organisations
through User Programmes and add to the list of commercial customers in the region.

Chair of Pacific Edge, Chris Gallaher, said: “The EY-Parthenon ratified, addressable market size for Pacific Edge
products in the USA is in excess of US$1.2 billion. We have a fantastic suite of products, are making traction with
our commercial strategy and are now starting to see some real movement in awareness and adoption of our
technology. Our Company is uniquely placed to capitalise on the demand for better, more accurate, less invasive
and more cost-effective diagnostics.”

The CEO David Darling said “the Company achieved good commercial growth with a 29% increase in laboratory
throughput to 14,400 tests, delivered 26% growth in revenue measured on a ‘like-for-like’ basis with last year and
6% growth in cash sales. Concluding that, there are very few young technology companies growing at this rate.”

17August 2018
Company Announcement

Shareholders voted in favour of all resolutions at the 2018 Annual Meeting.

Resolution For Against Abstain
Re-election of Anatole Masfen
205,778,350
98.14%
3,906,815
1.86%
345,037
Authorise the Directors to fix the
auditors’ remuneration
209,414,030
99.84%
344,463
0.16%
271,709
Increase in aggregate Directors’ fees to
$302,000 per annum
175,546,515
90.55%
18,311,814
9.45%
252,339

Copies of the annual meeting presentation and speeches are available on the company website
www.pacificedgedx.com.

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

Refer to www.cxbladder.com for more information.